Molecular Diagnostics News and Research

RSS

Myriad Publishes myPath™ Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath™ Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90 percent diagnostic accuracy. Melanoma is the most dangerous type of skin cancer and more than 76,000 new cases of melanoma are diagnosed each year in the United States.

6 Mar 2015

MRIGlobal awarded contract to develop Sample-to-Sequence system for diagnosis of infectious diseases

MRIGlobal today announced that it has been awarded a $14.8 million contract to develop an end-to-end next generation sequencing system for clinical diagnosis of infectious diseases.

23 Feb 2015

Biocartis to develop Rapid Ebola Virus Triage Test

Biocartis believes its Rapid Ebola Virus Triage Test could provide a sustainable solution for rapid detection of Ebola-infected patients even after the current Ebola outbreak.

From Biocartis 10 Feb 2015

Trovagene to sell underwritten public offering of common stock

Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced that it is offering to sell shares of its common stock in an underwritten public offering. The offering is expected to price on or about Friday, February 6, 2015.

6 Feb 2015

EKF Molecular Diagnostics collaborates with ANGLE for liquid biopsy development using Parsortix and PointMan technologies

EKF Molecular Diagnostics has agreed a collaboration with specialist medtech company ANGLE plc, to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with EKF Molecular's PointMan™ DNA enrichment technology as a liquid biopsy. If successful, the resulting simple blood test could enable the investigation of unexpected ultra-low level mutations in a patient's cancer for personalised cancer care.

29 Jan 2015

Cypher Genomics, Sequenom sign development agreement for noninvasive prenatal tests

Cypher Genomics, Inc., the leading genome informatics company, and Sequenom, Inc., the leading molecular diagnostics company, today announced a development agreement for next generation noninvasive prenatal tests (NIPT).

22 Jan 2015

EKF highlighting heat and humidity compatible POC hemoglobin analyzer at Arab Health 2015

EKF Diagnostics, the global diagnostics company, announces that it will be highlighting the robustness of its new DiaSpect Tm POC hemoglobin analyzer.

From EKF Diagnostics 15 Jan 2015

$Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies$

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies.

13 Jan 2015

Real-time RT-PCR TaqMan assay helps differentiate active pulmonary TB from LTBI

One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.

7 Jan 2015

Roche announces launch of cobas Liat System for on-demand testing in different settings

Roche today announced the launch of the cobas Liat System—a fast, compact , easy to use, molecular diagnostic platform, designed for on-demand testing in physician clinics, pharmacies and hospital lab settings.

16 Dec 2014

BGI Diagnostics develops ‘education hub’ to raise awareness about non-invasive prenatal testing

provider of accurate, reliable and affordable genetic tests and molecular diagnostics services has demonstrated its commitment to raising awareness about non-invasive prenatal testing (NIPT) by developing a dedicated ‘education hub’ as part of its new, highly informative website.

12 Dec 2014

Scientists receive NIH grants to explore sudden unexpected death in epilepsy

Nine groups of scientists will receive funding totaling $5.9 million in 2014 to work together on increasing the understanding of sudden unexpected death in epilepsy (SUDEP), the leading cause of death from epilepsy. The consortium becomes the second Center Without Walls, an initiative to speed the pace of research on difficult problems in epilepsy by promoting collaborative research.

9 Dec 2014

Case Western Reserve selected to lead $27.3 million international effort to identify causes of SUDEP

Case Western Reserve is one of two universities in the country selected to lead a $27.3 million international effort to identify the causes of a mysterious and deadly phenomenon that strikes people with epilepsy without warning.

9 Dec 2014

Researchers develop low-cost, electricity-free device for detecting DNA of infectious pathogens

Diagnosing HIV and other infectious diseases presents unique challenges in remote locations that lack electric power, refrigeration, and appropriately trained health care staff. To address these issues, researchers funded by the National Institutes of Health have developed a low-cost, electricity-free device capable of detecting the DNA of infectious pathogens, including HIV-1.

2 Dec 2014

Great Basin Scientific seeks FDA approval for Group B Strep assay

Great Basin Scientific, Inc., a molecular diagnostics company, today announced it has submitted its Group B Strep assay to the U.S. Food and Drug Administration for 510(k) clearance.

19 Nov 2014

EKF Molecular Diagnostics to present at AMP annual meeting

EKF, announces that senior executives from EKF Molecular Diagnostics including CEO, Andrew Webb, will be present at the Association for Molecular Pathology.

From EKF Diagnostics 6 Nov 2014

VTT develops innovative magnetometer for applications such as medical imaging

VTT Technical Research Centre of Finland has developed an innovative magnetometer that can replace conventional technology in applications such as neuroimaging, mineral exploration and molecular diagnostics. Its manufacturing costs are between 70 and 80 per cent lower than those of traditional technology, and the device is not as sensitive to external magnetic fields as its predecessors. The design of the magnetometer also makes it easier to integrate into measuring systems.

6 Nov 2014